Cargando…
Bevacizumab-Based Chemotherapy Triggers Immunological Effects in Responding Multi-Treated Recurrent Ovarian Cancer Patients by Favoring the Recruitment of Effector T Cell Subsets
Increasing evidence strongly suggests that bevacizumab compound impacts the immunological signature of cancer patients and normalizes tumor vasculature. This study aims to investigate the correlation between the clinical response to bevacizumab-based chemotherapy and the improvement of immune fitnes...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6462947/ https://www.ncbi.nlm.nih.gov/pubmed/30889935 http://dx.doi.org/10.3390/jcm8030380 |
_version_ | 1783410666167599104 |
---|---|
author | Napoletano, Chiara Ruscito, Ilary Bellati, Filippo Zizzari, Ilaria Grazia Rahimi, Hassan Gasparri, Maria Luisa Antonilli, Morena Panici, Pierluigi Benedetti Rughetti, Aurelia Nuti, Marianna |
author_facet | Napoletano, Chiara Ruscito, Ilary Bellati, Filippo Zizzari, Ilaria Grazia Rahimi, Hassan Gasparri, Maria Luisa Antonilli, Morena Panici, Pierluigi Benedetti Rughetti, Aurelia Nuti, Marianna |
author_sort | Napoletano, Chiara |
collection | PubMed |
description | Increasing evidence strongly suggests that bevacizumab compound impacts the immunological signature of cancer patients and normalizes tumor vasculature. This study aims to investigate the correlation between the clinical response to bevacizumab-based chemotherapy and the improvement of immune fitness of multi-treated ovarian cancer patients. Peripheral blood mononuclear cells (PBMCs) of 20 consecutive recurrent ovarian cancer patients retrospectively selected to have received bevacizumab or non-bevacizumab-based chemotherapy (Bev group and Ctrl group, respectively) were analyzed. CD4, CD8, and regulatory T cell (Treg) subsets were monitored at the beginning (T0) and after three and six cycles of treatment, together with IL10 production. A lower activated and resting Treg subset was found in the Bev group compared with the Ctrl group until the third therapy cycle, suggesting a reduced immunosuppressive signature. Indeed, clinically responding patients in the Bev group showed a high percentage of non-suppressive Treg and a significant lower IL10 production compared with non-responding patients in the Bev group after three cycles. Furthermore, clinically responding patients showed a discrete population of effector T cell at T0 independent of the therapeutic regimen. This subset was maintained throughout the therapy in only the Bev group. This study evidences that bevacizumab could affect the clinical response of cancer patients, reducing the percentage of Treg and sustaining the circulation of the effector T cells. Results also provide a first rationale regarding the positive immunologic synergism of combining bevacizumab with immunotherapy in multi-treated ovarian cancer patients. |
format | Online Article Text |
id | pubmed-6462947 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-64629472019-04-19 Bevacizumab-Based Chemotherapy Triggers Immunological Effects in Responding Multi-Treated Recurrent Ovarian Cancer Patients by Favoring the Recruitment of Effector T Cell Subsets Napoletano, Chiara Ruscito, Ilary Bellati, Filippo Zizzari, Ilaria Grazia Rahimi, Hassan Gasparri, Maria Luisa Antonilli, Morena Panici, Pierluigi Benedetti Rughetti, Aurelia Nuti, Marianna J Clin Med Article Increasing evidence strongly suggests that bevacizumab compound impacts the immunological signature of cancer patients and normalizes tumor vasculature. This study aims to investigate the correlation between the clinical response to bevacizumab-based chemotherapy and the improvement of immune fitness of multi-treated ovarian cancer patients. Peripheral blood mononuclear cells (PBMCs) of 20 consecutive recurrent ovarian cancer patients retrospectively selected to have received bevacizumab or non-bevacizumab-based chemotherapy (Bev group and Ctrl group, respectively) were analyzed. CD4, CD8, and regulatory T cell (Treg) subsets were monitored at the beginning (T0) and after three and six cycles of treatment, together with IL10 production. A lower activated and resting Treg subset was found in the Bev group compared with the Ctrl group until the third therapy cycle, suggesting a reduced immunosuppressive signature. Indeed, clinically responding patients in the Bev group showed a high percentage of non-suppressive Treg and a significant lower IL10 production compared with non-responding patients in the Bev group after three cycles. Furthermore, clinically responding patients showed a discrete population of effector T cell at T0 independent of the therapeutic regimen. This subset was maintained throughout the therapy in only the Bev group. This study evidences that bevacizumab could affect the clinical response of cancer patients, reducing the percentage of Treg and sustaining the circulation of the effector T cells. Results also provide a first rationale regarding the positive immunologic synergism of combining bevacizumab with immunotherapy in multi-treated ovarian cancer patients. MDPI 2019-03-18 /pmc/articles/PMC6462947/ /pubmed/30889935 http://dx.doi.org/10.3390/jcm8030380 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Napoletano, Chiara Ruscito, Ilary Bellati, Filippo Zizzari, Ilaria Grazia Rahimi, Hassan Gasparri, Maria Luisa Antonilli, Morena Panici, Pierluigi Benedetti Rughetti, Aurelia Nuti, Marianna Bevacizumab-Based Chemotherapy Triggers Immunological Effects in Responding Multi-Treated Recurrent Ovarian Cancer Patients by Favoring the Recruitment of Effector T Cell Subsets |
title | Bevacizumab-Based Chemotherapy Triggers Immunological Effects in Responding Multi-Treated Recurrent Ovarian Cancer Patients by Favoring the Recruitment of Effector T Cell Subsets |
title_full | Bevacizumab-Based Chemotherapy Triggers Immunological Effects in Responding Multi-Treated Recurrent Ovarian Cancer Patients by Favoring the Recruitment of Effector T Cell Subsets |
title_fullStr | Bevacizumab-Based Chemotherapy Triggers Immunological Effects in Responding Multi-Treated Recurrent Ovarian Cancer Patients by Favoring the Recruitment of Effector T Cell Subsets |
title_full_unstemmed | Bevacizumab-Based Chemotherapy Triggers Immunological Effects in Responding Multi-Treated Recurrent Ovarian Cancer Patients by Favoring the Recruitment of Effector T Cell Subsets |
title_short | Bevacizumab-Based Chemotherapy Triggers Immunological Effects in Responding Multi-Treated Recurrent Ovarian Cancer Patients by Favoring the Recruitment of Effector T Cell Subsets |
title_sort | bevacizumab-based chemotherapy triggers immunological effects in responding multi-treated recurrent ovarian cancer patients by favoring the recruitment of effector t cell subsets |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6462947/ https://www.ncbi.nlm.nih.gov/pubmed/30889935 http://dx.doi.org/10.3390/jcm8030380 |
work_keys_str_mv | AT napoletanochiara bevacizumabbasedchemotherapytriggersimmunologicaleffectsinrespondingmultitreatedrecurrentovariancancerpatientsbyfavoringtherecruitmentofeffectortcellsubsets AT ruscitoilary bevacizumabbasedchemotherapytriggersimmunologicaleffectsinrespondingmultitreatedrecurrentovariancancerpatientsbyfavoringtherecruitmentofeffectortcellsubsets AT bellatifilippo bevacizumabbasedchemotherapytriggersimmunologicaleffectsinrespondingmultitreatedrecurrentovariancancerpatientsbyfavoringtherecruitmentofeffectortcellsubsets AT zizzariilariagrazia bevacizumabbasedchemotherapytriggersimmunologicaleffectsinrespondingmultitreatedrecurrentovariancancerpatientsbyfavoringtherecruitmentofeffectortcellsubsets AT rahimihassan bevacizumabbasedchemotherapytriggersimmunologicaleffectsinrespondingmultitreatedrecurrentovariancancerpatientsbyfavoringtherecruitmentofeffectortcellsubsets AT gasparrimarialuisa bevacizumabbasedchemotherapytriggersimmunologicaleffectsinrespondingmultitreatedrecurrentovariancancerpatientsbyfavoringtherecruitmentofeffectortcellsubsets AT antonillimorena bevacizumabbasedchemotherapytriggersimmunologicaleffectsinrespondingmultitreatedrecurrentovariancancerpatientsbyfavoringtherecruitmentofeffectortcellsubsets AT panicipierluigibenedetti bevacizumabbasedchemotherapytriggersimmunologicaleffectsinrespondingmultitreatedrecurrentovariancancerpatientsbyfavoringtherecruitmentofeffectortcellsubsets AT rughettiaurelia bevacizumabbasedchemotherapytriggersimmunologicaleffectsinrespondingmultitreatedrecurrentovariancancerpatientsbyfavoringtherecruitmentofeffectortcellsubsets AT nutimarianna bevacizumabbasedchemotherapytriggersimmunologicaleffectsinrespondingmultitreatedrecurrentovariancancerpatientsbyfavoringtherecruitmentofeffectortcellsubsets |